---
title: "Apellis Pharmaceuticals Says US FDA Grants Priority Review to Empaveli Application for Rare Kidney Diseases"
description: "Apellis Pharmaceuticals announced that the US FDA has accepted its supplemental new drug application for Empaveli, aimed at treating rare kidney diseases C3 glomerulopathy and primary immune complex m"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/234066155.md"
published_at: "2025-04-01T13:05:26.000Z"
---

# Apellis Pharmaceuticals Says US FDA Grants Priority Review to Empaveli Application for Rare Kidney Diseases

> Apellis Pharmaceuticals announced that the US FDA has accepted its supplemental new drug application for Empaveli, aimed at treating rare kidney diseases C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis. The application is supported by late-stage trial results showing significant reduction in proteinuria and stabilization of kidney function. The FDA granted Priority Review, with a decision expected by July 28.

Apellis Pharmaceuticals said Tuesday that the US Food and Drug Administration has accepted its supplemental new drug application for Empaveli, or pegcetacoplan, to treat C3 glomerulopathy and primary immune complex membranoproliferative glomerulonephritis, both rare kidney diseases.

The company said the application is based on results from a late-stage trial that achieved its primary endpoint of "statistically significant" reduction in proteinuria and indicated stabilization of kidney function in patients treated with Empaveli.

The agency granted the application Priority Review and scheduled a decision date of July 28, Apellis said.

### Related Stocks

- [APLS.US - Apellis Pharma](https://longbridge.com/en/quote/APLS.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Astellas Izervay campaign casts HCPs as ‘Partners in Protection’ | Astellas Pharma has launched the "Partners in Protection" campaign for its Izervay treatment, aimed at educating retina  | [Link](https://longbridge.com/en/news/275936312.md) |
| Apellis CEO Cedric Francois Reports Sale of Common Shares | Cedric Francois, CEO of Apellis Pharmaceuticals Inc., reported the sale of common shares of the company. The full filing | [Link](https://longbridge.com/en/news/273555525.md) |
| Apellis Pharmaceuticals, Inc. $APLS Shares Sold by Savant Capital LLC | Savant Capital LLC reduced its stake in Apellis Pharmaceuticals, Inc. (NASDAQ: APLS) by 50.7% in Q3, now holding 48,886  | [Link](https://longbridge.com/en/news/275591859.md) |
| Apellis Pharmaceuticals: European Aspaveli Validation and Growing U.S. C3G/IC-MPGN Traction Underpin Buy Rating | William Blair analyst Lachlan Hanbury Brown has maintained a Buy rating on Apellis Pharmaceuticals (APLS) due to the rec | [Link](https://longbridge.com/en/news/272856422.md) |
| Apellis CEO Cedric Francois Reports Disposal of Common Shares | Cedric Francois, CEO of Apellis Pharmaceuticals Inc., has reported the disposal of common shares of the company. The ful | [Link](https://longbridge.com/en/news/272748153.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.